
    
      OBJECTIVES:

      Primary

        -  Determine the objective response rate at 6 months in patients with systemic mastocytosis
           treated with thalidomide.

      Secondary

        -  Determine the tolerability of this drug in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive oral thalidomide once daily for 6 months in the absence of disease
      progression.
    
  